Is the Pharmaceutical Industry Open For Innovation? By Dr Jackie Hunter CBE Open innovation is the hot topic in many industries and this approach has the potential to make a radical difference to the costs of drug discovery and development in the pharmaceutical industry. But there are also barriers to… Read More
High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative By Dr Larry A. Sklar and Dr Bruce S. Edwards Commercial flow cytometers became widely established in research and clinical laboratories in the 1980s. Once the domain of immunologists and hematologists for cell sorting and analysis,… Read More
Biomarkers Make Their Mark on Current Research and Drug Development Trends By Stephane Parent and Dr Gregory Cosentino Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007… Read More
Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More
Personalised Medicine Market and Regulatory Landscape By Dr Enal Razvi and Dr Patricia Hurley Over the past several years, there has been continuing interest in the deployment of personalised medicine via the development of companion diagnostics/therapeutics. The leading edge of this discipline is in the cancer personalised medicine arena where… Read More
Utilising 3D nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening By Professor Jian Tajbakhsh, Professor Arkadiusz Gertych and Professor Daniel L Farkas Since epigenetic changes are thought to underlie a wide range of complex diseases, the scope of epigenetic drug therapy is likely to expand, as epigenetic… Read More
By Dr Stephen Naylor and Toby Cole In this article we describe the current state of Companion Diagnostics and its impact on the pharmaceutical sector, and the need for Companion Diagnostics in the drug discovery and development process. This perspective is augmented by a consideration of the development of Companion… Read More
Free Online Resources Enabling Crowd-Sourced Drug Discovery By Dr Antony J. Williams, Valery Tkachenko, Dr Chris Lipinski, Professor Alexander Tropsha and Dr Sean Ekins The availability of freely accessible online resources to enable and support drug discovery has blossomed in recent years. The PubChem platform is now accompanied by a… Read More
Current and Emerging Trends in Cell-Based Assays - Roundtable In 2009 Drug Discovery World hosted a collegial-style roundtable discussion on the present and emerging developments in this exciting and now, fundamental area of drug discovery. The participants are recognised to be thought leaders in this field and represent the pharma,… Read More
Custom Carbon-14 Radiolabelling: Investing to meet new challenges By Dave Roberts One consequence of an increasing demand from regulators for robust quantitative data on the behaviour of new drugs in man and for information on the fate of pharmaceuticals in the environment, has been an increase in demand for carbon-14… Read More
Maximising the impact of technologies on drug discovery through portfolio management By Charles S. Dormer, Dr Mark Beggs, Dr Lynn Brennan and Roanna London The opportunities to invest in new technologies in drug discovery are broad and extensive. Knowing where to place your investment and ensuring return on these investments… Read More
Multiplexing for biological relevance in high throughput screening By William P. Downey, Dr Jennifer Hartigan and Cindy Liu The multiplexed assay is a technique used increasingly in high throughput screening (HTS) labs to study the complex environment of a target, according to HighTech Business Decisions’ (HTBD) industry report High Throughput… Read More
By Dr Susanta K. Sarkar The current challenges facing drug discovery and development in terms of attrition are well documented. This article discusses how molecular imaging approaches from bench to bedside can not only streamline drug development, but also open up new opportunities in the treatment management of targeted therapies. Read More
Share Share Tweet Email A perspective on scientific innovation in the pharmaceutical industry A perspective on scientific innovation in the pharmaceutical industry By Dr Joseph B. Bolen With a tarnished reputation and a lack of sustainable innovation this article argues that, maybe, it is time for the pharmaceutical industry to… Read More
Automation Of Solid/Powder Dispensing: Much needed, but cautiously used! By Dr John Comley This article investigates solid/powder dispensing in pharma and biotech, examines where it is most used, whether there exists a need to apply automation and what is motivating its wider use today. It reveals how concerns over problematic… Read More
LIMS vs ELNs - Arch enemies or best of friends? By David Morris Since the first appearance of laboratory information management systems (LIMS) in the late 1960s, this technology has become commonplace in many, if not most, research and commercial laboratories. This considerable development in LIMS is in response to… Read More